Manila Bulletin
Sinopharm, Sinovac to apply for emergency use in PH, says envoy
Sinopharm and Sinovac, two Chinese vaccine manufacturers, are expected to file for emergency use authorization (EUA) with the Philippine Food and Drug Administration (FDA) this week.
Ambassador to Beijing Jose Santiago "Chito" Sta. Romana confirmed this, stating that the embassy is facilitating communication between the companies and the Inter-Agency Task Force (IATF).
Sinopharm's vaccine has reportedly shown 79% efficacy in preventing COVID-19 and has already been approved for public use in China.
Sinovac's vaccine has a reported efficacy rate of 50%, which meets the minimum standard set by the World Health Organization.
The FDA has also received an EUA application from Pfizer for its vaccine developed in partnership with BioNTech.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
British pharmaceutical firm AstraZeneca has applied for emergency use authorization (EUA) for its COVID-19 vaccine in the Philippines, marking the second such application after Pfizer.
+1
Read more →
Pfizer-BioNTech has officially filed for an emergency use authorization (EUA) for its COVID-19 vaccine in the Philippines on December 23, 2020.
Read more →
Russia's Gamaleya Research Institute has applied for an emergency use authorization (EUA) for its Sputnik V vaccine in the Philippines.
Read more →
The Philippines has secured 25 million doses of the COVID-19 vaccine from the Chinese firm Sinovac, with the first batch expected in February.
Read more →
The Philippine FDA has approved Clover Biopharmaceuticals' application for Phase III clinical trials of its COVID-19 vaccine in the country.
Read more →